Newsroom | 36358 results
Sorted by: Latest
-
Presidio Medical™ Receives IDE Approval for Ultra Low Frequency (ULF™) Neuromodulation Clinical Study and Appoints Dimas Jiménez as Chief Financial Officer
SAN MATEO, Calif.--(BUSINESS WIRE)--Presidio Medical, Inc., a global clinical-stage medical device company developing a transformational Ultra Low Frequency (ULF™) neuromodulation platform, received IDE approval from the FDA, enabling the company to commence a global, pivotal, randomized controlled trial, the FULFILL Study, in the United States and Australia. ULF Neuromodulation will be delivered via leads implanted in the epidural space, also known as Spinal Cord Stimulation (SCS). Presidio is...
-
GE HealthCare advances precision care with MIM Encore™ to deliver next-generation digital imaging and workflow solutions
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) proudly announces the combination of GE HealthCare’s proprietary features and algorithms with MIM Encore, marking a significant milestone in its mission to deliver precision care through advanced digital solutions. This implementation brings powerful new features to healthcare organizations boasting GE HealthCare systems alongside MIM software with MIM Encore, a cutting-edge, single platform design based on user input to help enhance diagno...
-
AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies
AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a leader in AI-powered drug discovery and biotherapeutics, today announced compelling in vitro results demonstrating that its artificial intelligence (AI)-designed GLP-1 receptor agonist (GLP-1RA) peptide sequences achieve comparable or superior receptor activation to Semaglutide, a benchmark GLP-1 therapy and one of the most commercially successful drugs in the world. The in vitro analysis was conducted by an independ...
-
Sky Labs at Forefront of Cuffless Blood Pressure Monitoring
SEOUL, South Korea--(BUSINESS WIRE)--Sky Labs captures global attention at the ESH 2025 with the world’s first ring-type cuffless blood pressure monitor....
-
Sky Labs nimmt eine Vorreiterrolle im Bereich der manschettenlosen Blutdruckmessung ein
SEOUL, Südkorea--(BUSINESS WIRE)--Sky Labs, ein südkoreanisches Start-up im Bereich digitale Gesundheitsversorgung, erregte auf der European Society of Hypertension (ESH) 2025 in Mailand, Italien, mit der Vorstellung des weltweit ersten ringförmigen Blutdruckmessgeräts ohne Manschette weltweit Aufmerksamkeit. Am 25. Mai rückte im Rahmen eines Symposiums mit dem Titel „Breaking Boundaries in Hypertension Care: A New Era with Cuffless Blood Pressure Monitoring“ die manschettenlose Blutdrucktechno...
-
First Clinical Study of SeptAlign™ Implant Demonstrates Safety and Efficacy in Treating Nasal Septal Deviation While Preserving Cartilage
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spirair, Inc., an early-stage company developing minimally invasive solutions to help ENTs improve patient care, today announced the publication of the first clinical study evaluating its SeptAlign™ implant. The positive 12-month outcomes demonstrate the safety and efficacy of this novel bioabsorbable device, which offers a cartilage-sparing approach to traditional septoplasty for the treatment of nasal septal deviation (NSD). NSD is a leading cause...
-
Simulations Plus to Participate in the Citizens Medical Devices and Healthcare Services Forum
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that Shawn O’Connor, Chief Executive Officer, will be participating in the Citizens Medical Devices and Healthcare Services Forum taking place in Boston, Massachusetts. Mr. O’Connor will host one-on-one...
-
Epiminder Announces Publication of Landmark Clinical Trial Confirming Safety and Efficacy of the Minder® System
MELBOURNE, Australia & DALLAS--(BUSINESS WIRE)--Epiminder, a pioneer in implantable continuous EEG monitoring (iCEM™), today announced the publication of results from its landmark UMPIRE (sUb-scalp Monitoring ePileptic seIzuREs) clinical trial in Epilepsia validating the safety and efficacy of its iCEM. The study, conducted across leading Australian hospitals, demonstrated Minder’s ability to capture high-quality EEG data for extended periods that are comparable to current standard of care scal...
-
Establishment Labs Hosting Investor Day on June 12
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, will host its previously announced analyst and investor event in New York City on June 12, 2025 beginning at 1pm ET. A live and archived webcast of presentations and Q&A sessions on June 12 will be available on the "Investors" section of the Establishment Labs website at www.es...
-
KORU Medical Systems to Join Russell 3000® and Russell 2000® Indexes
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell indexes annual reconstitution, effective after the US...